On October 1, 2021 BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company"), a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, reported that new clinical and preclinical data will be presented in six posters and one presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), being held both in person and virtually from November 10 – 14, 2021 (Press release, BioNTech, OCT 1, 2021, View Source [SID1234590644]). The presentations will include new data from multiple programs across various drug classes along with first-in-human data for three programs. This is the largest data collection the company will present at a scientific meeting, showcasing BioNTech’s diversified oncology pipeline.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The data we will be presenting at SITC (Free SITC Whitepaper) 2021 is indicative of our continued pursuit of pathbreaking science and the development of our platform technologies that tailor anti-cancer therapies to individual patient needs," said Özlem Türeci, M.D., Co-Founder and Chief Medical Officer at BioNTech. "We are encouraged by the considerable progress within our oncology portfolio seeing multiple programs now coming to fruition. They represent critical steps for us towards bringing cancer immunotherapy into the next generation and we are looking forward to sharing the data with the scientific community at a key conference."

Presentation Details:

Antibodies, Next-Generation Checkpoint Immunomodulators

Program: BNT312
Presentation Title: First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody-CD40×4-1BB (GEN1042) in patients with advanced solid tumors
Session Title: Concurrent Rapid Oral Abstract Presentation Session 206: Clinical
Speaker: Melissa L. Johnson, M.D., Lead Investigator, Associate Director, Lung Cancer Research, Sarah Cannon Cancer Institute, TriStar Centennial Medical Center
Abstract Number: 493
Date & Time: Saturday, November 13, 2021, 12:45 pm – 1:45 pm ET

This product candidate GEN1042 (BNT312) is being co-developed by Genmab and BioNTech under an agreement in which the companies share all costs and future profits on a 50:50 basis.

Poster Details:

All data presented in poster presentations at the poster hall will be made available as virtual ePosters throughout the SITC (Free SITC Whitepaper) 36th Virtual Annual Meeting.

mRNA Therapeutics, FixVac

Program: BNT111
Poster Title: An RNA lipoplex (RNA-LPX) vaccine demonstrates strong immunogenicity and promising clinical activity in a Phase I trial in cutaneous melanoma patients with no evidence of disease at trial inclusion
Abstract Number: 15965
Date & Time: Friday, November 12, 2021, 7:00 am – 8:30 pm ET

Program: BNT112
Poster Title: A first-in-human (FIH) Phase I/IIa clinical trial assessing a ribonucleic acid lipoplex (RNA-LPX) encoding shared tumor antigens for immunotherapy of prostate cancer; preliminary analysis of PRO-MERIT
Abstract Number: 15941
Date & Time: Friday, November 12, 2021, 7:00 am – 8:30 pm ET

Engineered Cell Therapies, NEO-STIM

Program: BNT221
Poster Title: BNT221, an autologous neoantigen-specific T-cell product for adoptive cell therapy of metastatic ovarian cancer
Abstract Number: 201
Date & Time: Friday, November 12, 2021, 7:00 am – 8:30 pm ET

Antibodies, Next-Generation Checkpoint Immunomodulators

Program: BNT311
Short Presentation Title: Peripheral and tumoral immune activity in the expansion part of the first-in-
human DuoBody-PD-L1×4-1BB (GEN1046) trial
Abstract Number: 516
Date & Time: Saturday, November 13, 2021, 7:00 am – 8:30 pm ET

The product candidate GEN1046 (BNT311) is being co-developed by Genmab and BioNTech under an agreement in which the companies share all costs and future profits on a 50:50 basis.

Program: BNT311
Short Presentation Title: Dose selection for DuoBody-PD-L1×4-1BB (GEN1046) using a semimechanistic
pharmacokinetics/pharmacodynamics model that leverages preclinical and clinical data
Abstract Number: 786
Date & Time: Saturday, November 13, 2021, 7:00 am – 8:30 pm ET

The product candidate GEN1046 (BNT311) is being co-developed by Genmab and BioNTech under an agreement in which the companies share all costs and future profits on a 50:50 basis.

Small Molecule Immunomodulators, Toll-like Receptor (TLR) Binding platform

Program: BNT411
Short Presentation Title: Preliminary safety, PK/PD and efficacy results from a first-in-human phase I/IIa clinical trial of BNT411, a systemic Toll-like receptor 7 agonist in patients with solid tumors
Abstract Number: 525
Date & Time: Friday, November 12, 2021, 7:00 am – 8:30 pm ET